Clinical Trial Update: Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ganciclovir/valganciclovir for prevention of CMV reactivation in patients with acute lung injury and respiratory failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome
• Respiratory Failure

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-09-13